Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1081 to 1081 of 1081 entries
Sorted by: Best Match Show Resources per page
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells.

International journal of molecular sciences

Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T.
PMID: 34884875
Int J Mol Sci. 2021 Dec 02;22(23). doi: 10.3390/ijms222313071.

Hepatocellular carcinoma (HCC) is one of the major causes of cancer-related deaths worldwide. Sorafenib has been used as a first-line systemic treatment for over a decade. However, resistance to sorafenib limits patient response and presents a major hurdle during...

Cite
Shi T, Iwama H, Fujita K, et al. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci. 2021;22(23)doi: 10.3390/ijms222313071.
Shi, T., Iwama, H., Fujita, K., Kobara, H., Nishiyama, N., Fujihara, S., Goda, Y., Yoneyama, H., Morishita, A., Tani, J., Yamada, M., Nakahara, M., Takuma, K., & Masaki, T. (2021). Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. International journal of molecular sciences, 22(23), . https://doi.org/10.3390/ijms222313071
Shi, Tingting, et al. "Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells." International journal of molecular sciences vol. 22,23 (2021). doi: https://doi.org/10.3390/ijms222313071
Shi T, Iwama H, Fujita K, Kobara H, Nishiyama N, Fujihara S, Goda Y, Yoneyama H, Morishita A, Tani J, Yamada M, Nakahara M, Takuma K, Masaki T. Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells. Int J Mol Sci. 2021 Dec 02;22(23). doi: 10.3390/ijms222313071. PMID: 34884875; PMCID: PMC8657692.
Copy Download .nbib Format: NLM
Showing 1081 to 1081 of 1081 entries